Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)

Creative Medical Technology Holdings, Inc., or CELZ, is a commercial-stage biotechnology company operating in the field of regenerative medicine. The company specializes in the development and commercialization of stem cell-based therapies for various medical conditions. These therapies include CaverStem, FemCelz, StemSpine, and ImmCelz.

The company's main business activities involve the development and commercialization of these therapies. CELZ generates revenue primarily through the sale of disposable bone marrow aspiration kits to physicians who use them to perform the CaverStem and FemCelz procedures. The company also contracts with physicians to purchase kits and provides exclusivity in their market through patent protection, marketing support, and training.

CELZ's primary products and services include CaverStem, a clinically proven procedure that utilizes a patient's own stem cells to treat erectile dysfunction (ED). FemCelz is a procedure that uses a patient's own stem cells to improve female sexual function. StemSpine is a regenerative stem cell procedure that uses a patient's own stem cells to treat chronic lower back pain. ImmCelz is a personalized supercharged immune therapy platform that utilizes a patient's own extracted immune cells that are then reprogrammed by culturing them outside the patient's body with optimized secreted factors.

The CaverStem and FemCelz procedures involve harvesting stem cells from bone marrow, filtering out red blood cells, and injecting the cells into the patient's corpus cavernosum or the pubocervical fascia, skene's glands, and around the peri-clitoral area to stimulate muscle and blood vessel regeneration. The StemSpine procedure involves administering the cells into muscles surrounding the area of lower back pain to stimulate blood vessel regeneration.

CELZ has filed patents for its technologies, including U.S. Patent No. 8,372,797 for the treatment of erectile dysfunction using stem cells, and has registered trademarks for CaverStem, FemCelz, and StemSpine. The company has also announced positive results from clinical trials for its products, including a three-year follow-up study for its StemSpine procedure, which showed continued efficacy and no serious adverse effects. CELZ has also filed an application with the USPTO to trademark ImmCelz.

The company's marketing strategy includes a multifaceted approach that includes a robust website, online advertising, social media, in-office flyers and banners, patient testimonials, and informative videos. The company has marketed its CaverStem and FemCelz procedures in eight markets across the United States.

In the field of regenerative medicine, CELZ competes with many pharmaceutical, biotechnology, and medical device companies, as well as other private and public stem cell companies involved in the development and commercialization of cell-based medical technologies and therapies. Many of these competitors have substantially greater financial, technological, research and development, marketing, and personnel resources than CELZ.

CELZ is regulated by the FDA and other regulatory agencies, which impose substantial requirements upon the clinical development, approval, manufacture, distribution, and marketing of medical products, including drugs, biologics, and medical devices. The company must comply with applicable regulations, including the FDA's Human Cells, Tissues, and Cellular and Tissue-Based Products Regulations, the FDA's drug and biological product regulations, and the FDA's medical device regulations.